Volume | 286,662 |
|
|||||
News | (2) | ||||||
Day High | 9.085 | Low High |
|||||
Day Low | 8.57 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Pulse Biosciences Inc | PLSE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.82 | 8.57 | 9.085 | 8.71 | 8.40 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,992 | 286,662 | $ 8.71 | $ 2,496,480 | - | 2.36 - 13.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:25:12 | formt | 300 | $ 7.70 | USD |
Pulse Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
476.78M | 54.99M | - | 700k | -58.51M | -1.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Pulse Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PLSE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.43 | 9.675 | 7.93 | 8.69 | 121,087 | -1.73 | -18.35% |
1 Month | 10.35 | 11.6398 | 7.93 | 9.69 | 146,972 | -2.65 | -25.60% |
3 Months | 10.00 | 11.6398 | 7.77 | 9.15 | 171,965 | -2.30 | -23.00% |
6 Months | 4.14 | 13.62 | 3.78 | 8.83 | 217,867 | 3.56 | 85.99% |
1 Year | 2.8522 | 13.62 | 2.36 | 7.70 | 195,006 | 4.85 | 169.97% |
3 Years | 22.75 | 29.16 | 1.18 | 7.43 | 150,655 | -15.05 | -66.15% |
5 Years | 17.60 | 45.82 | 1.18 | 9.85 | 125,711 | -9.90 | -56.25% |
Pulse Biosciences Description
Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. |